Leukemia M5 intermediate-risk depends on the patient’s condition and how well the chemotherapy is working to determine whether a bone marrow transplant is needed. Leukemia M5 is a type of acute non-lymphocytic leukemia, also known as acute monocytic leukemia, which is complex and variable. Bone marrow transplantation is not necessary for all leukemia M5 types, and is not necessary if chemotherapy is effective. Stem cell transplantation is not necessary unless the patient is at high risk or has relapsed. Drugs include cytarabine, etc. The decision of chemotherapy or transplantation depends on the patient’s specific situation, such as chromosomal mutations, blood counts at the time of disease onset, fusion mutations, sensitivity to chemotherapy, and so on. In order to achieve deep remission of the disease, as well as intermediate-risk patients who are resistant to chemotherapeutic drugs, autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation can be chosen. For the same disease, patients with different physical conditions and at different stages of the disease are treated differently and should be treated in a standardized manner under the guidance of their doctors.